Lovastatin and Pembrolizumab for Head and Neck Cancer
Phase 2
28
about 4.1 years
18+
2 sites in GA
What this study is about
This trial is testing if lovastatin and pembrolizumab are effective in treating patients with recurrent or metastatic head and neck cancer. Lovastatin is a drug that may kill tumor cells, while pembrolizumab is an immunotherapy drug that helps the immune system fight cancer. The goal is to see if giving both drugs together can improve outcomes for these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Pembrolizumab
- 2.Take Lovastatin
- 3.Undergo Biospecimen Collection
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lovastatin, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
oral (Oral Tablet), infusion
Primary: Objective response rate (ORR)
Secondary: Incidence of adverse events (AEs) and serious adverse events (SAEs), Overall survival (OS), Progression free survival (PFS)
diagnostic, imaging
Oncology